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Abstract 
Objectives: To determine women’s experiences of brachytherapy for cervical cancer. 
Key findings: Nineteen studies were included for data extraction/synthesis. Twelve studies focussed 
on psychological issues, seven on pharmacological aspects of women’s experiences. Themes of 
anxiety, distress, pain, informational needs and non-pharmacological interventions were found. Nine 
out of ten psychological studies described brachytherapy as a distressing experience causing anxiety 
and distress for most women. Non-pharmacological interventions were found to be effective and 
inexpensive adjuncts. Peri and post-operative pharmacological management was variable, but 
duration of procedure was an important factor.  
Conclusion: Brachytherapy for gynaecological cancer causes varying levels of pain, anxiety and 
distress. To improve women’s experiences there needs to be better pain management, patient 
information and the development of non-pharmacological interventions. Future recommendations 
are to develop clinical support guidelines, audit the quality of services and develop effective 
interventions to improve women’s experiences of brachytherapy for locally advanced cervical 
cancer. 
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*Abstract
Highlights: 
 Lack of studies examining patient experience in the context of technical advances in 
brachytherapy. 
 Brachytherapy for gynaecological cancer causes varying levels of pain, anxiety and distress. 
 Pharmacological approaches should be explored and developed to minimise pain and 
discomfort  
 Non-pharmacological interventions should be explored to improve women’s experiences  
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The experiences of women receiving brachytherapy for cervical cancer: a systematic literature 
review 
Introduction 
The worldwide incidence of cervical cancer has been estimated as 528,000 newly diagnosed cases 
annually and is the 4th most common cancer in women.1 Global incidence is highest in less developed 
countries (85%) with higher mortality rates where there is less access to diagnostic and therapeutic 
health services.1 Approximately 3,000 new cases of cervical cancer are diagnosed each year in the 
UK2. Despite a comprehensive national cervical screening programme, about a third of these women 
present with locally advanced disease, unsuitable for surgery. For about 1,000 women per year 
chemotherapy and radiotherapy including brachytherapy is standard treatment in the UK. 
Brachytherapy is a type of internal radiation therapy where a radioactive source is placed close to 
the tumour. To deliver the radiation dose to treat locally advanced cervix cancer, hollow applicators 
are placed in the uterus and vagina and the radioactive source is passed into the hollow applicators. 
This technique is currently offered at 42 UK radiotherapy centres.3   
In the past treatment machines used low dose rate (LDR) radioactive sources with treatment times 
typically 2-3 days. Treatment was delivered in a shielded radiation room on a ward. Patients were 
immobilised and in isolation to prevent irradiation of hospital staff. The radiation could be switched 
off for short periods to allow nursing care, medication delivery and food and drink supplies. However 
any break in treatment was minimised to keep overall time as short as possible. Visitors were kept to 
a minimum or prohibited. This was the most common type of brachytherapy in the UK until the early 
2000s. Due to lack of availability of replacements for the LDR afterloader caesium sources most UK 
departments purchased a high dose rate (HDR) afterloader so the treatment could be delivered in 
minutes3. The newer HDR system requires multiple fractions (typically 3-5) to give the equivalent 
radiobiological effect as LDR treatment.  
Recent technical developments include brachytherapy applicators compatible with Computerised 
Tomography (CT) and Magnetic Resonance Imaging (MRI) to enable acquisition of CT and MRI scans 
with applicators inside patients. Previously treatment planning was 2-dimensional and dose 
prescribed to a defined point. However with new treatment planning software 3-dimensional CT and 
MR images are used to prescribe dose to a volume. With improved imaging and planning it is 
possible to minimise dose to structures that are sensitive to radiation, known as organs at risk 
(OARs). Excessive radiation dose to OARs would cause acute and long term side effects. The 
introduction of extra needle applicators into the cervix tumour has allowed dose escalation which 
has been shown to increase local tumour control to 85-100%.4, 5, 6, 7, 8 As the planning has become 
more complex, with the requirement to draw the tumour (target volume) and OARs onto the 3D 
images, so the time taken to plan treatments has increased. Anecdotally it is reported that planning 
time has increased from a matter of minutes to 2-5 hours.  
Some centres give HDR brachytherapy as a day case procedure.9, 10 Patients arrive early in the 
morning for anaesthetic and theatre procedure for applicator/needle insertion, then CT and/or MR 
imaging, planning, treatment delivery, applicator removal and discharged home later the same day. 
Some centres keep patients in hospital overnight with applicators/needles remaining in place and 
repeat treatments over 2-3 days.11 Although the patient does not need to remain in isolation in a 
radiation treatment room like the old LDR treatments, it does mean they have to remain immobile in 
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bed for a long time. However, their treatment may be completed in one hospital visit and only 
require one theatre and anaesthetic procedure. Some centres do two treatments for one theatre 
procedure with one overnight stay, then repeated a week later.12  Some centres deliver the radiation 
in pulses, using a source typically 1/10th the activity of a HDR source which is pulsed hourly (Pulsed 
dose rate, PDR). This is usually given in an isolation room on a ward. The introduction of interstitial 
needles may have led to the potential for greater pain for women, and some centres have altered 
their anaesthesia and analgesia techniques to help women cope with this.10 
There are some benefits and disadvantages for these different methods of dose delivery but the 
impact of these technical and scheduling changes on patients is unknown. A systematic literature 
review (SLR) was carried out with the aim to determine women’s experiences of brachytherapy for 
cervical cancer so that consideration could be given to patient’s needs.  
Methods  
The SLR was carried out following PRISMA guidelines (Preferred Reporting Items for Systematic 
Reviews and Meta-Analyses),13 registered on PROSPERO International prospective register of 
systematic reviews, and completed in May 2017.14 
A systematic literature search was carried out independently by two researchers. Five databases: 
MEDLINE; CINAHL; EMBASE; PsychINFO and AMED were selected to ensure journals would be 
included that were authored and read by oncologists, anaesthetists, psychologists, nurses and 
radiographers, i.e. all those involved in the care of women during brachytherapy. No restriction to 
publication date was applied as it was important to include older papers that referred to LDR 
brachytherapy as the longer duration of treatment may report experiences and coping strategies 
that are also relevant to newer techniques of HDR brachytherapy with multiple fractions per 
insertion and PDR brachytherapy. The search strategy was detailed on the PROSPERO entry.14 
Key terms used for the search are listed in Table 1. 
Table 1- Key search terms 
Additional sources were searched, including grey literature (Open Grey, GreyNet International, UK 
Institutional Repository Search and The Healthcare Management Information Consortium), three 
clinical experts from different professions, snowballing of reference lists of included studies and 
reverse snowballing to insure that no relevant studies had been missed out. Inclusion criteria were 
any study which focussed on women’s experiences of brachytherapy rather than other factors such 
as local control, survival or radiation dose planning. Studies were included if their main focus was 
women’s experiences of brachytherapy for gynaecological cancers. As there was no set definition of 
“patient experience” it was decided by the two researchers that studies where pain scores were 
reported by the patients would be included. There was no restriction on study design or setting. It 
was agreed that full text articles were required as abstracts would not contain enough detail for 
analysis, and English language only could be considered due to prohibitive costs of translation 
services. 
Duplicate studies and those reporting the same cohort of patients were removed. The two 
researchers independently screened firstly by titles then abstracts to exclude articles that were 
obviously irrelevant. Full text articles were obtained and full texts in other languages were excluded 
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at this point. Any disagreement between the two researchers was discussed at the full text stage and 
any remaining discrepancies discussed with a third party (academic supervisor- third author) to 
make a final decision. Assessment of the quality of papers was carried out independently by the two 
researchers using specific Critical Appraisal Skills Programme (CASP) tool for each type of study 
design.15 The results were collated, to improve internal validity and reduce risk of subjective bias. 
Papers deemed as poor quality (more than 75% No or can’t tell to CASP tool questions) were 
excluded before data extraction and synthesis. This step was a change from the method described in 
the original PROSPERO publication due to the larger than anticipated number of eligible studies and 
time limitation to complete data extraction and synthesis and to avoid degradation of findings with 
poor data. A bespoke data extraction tool was created ‘a priori’ and data extraction was carried out 
by one researcher (first author) and checked by the second researcher (second author). Data 
synthesis was carried out by first researcher, then discussed with the second researcher and agreed 
upon. 
Results 
The search strategy produced 727 articles and removing duplicates reduced this to 562. Searching of 
grey literature produced no additional articles. Screening of titles excluded 438 articles leaving 124. 
Screening of abstracts excluded 78 articles to leave 44. Full text articles were obtained at this point 
and snowballing and reverse snowballing found 2 new articles. The 46 full text articles were 
examined and a further 24 were rejected for the reasons shown in table 2. There were 22 remaining 
articles. Five studies were randomised controlled studies (RCTs),16, 17, 18, 19, 20 two case control 
studies,21, 22 nine cohort studies,11, 12, 23, 24, 25, 26, 27, 28, 29 five qualitative studies30, 31, 32, 33, 34 and 1 
systematic literature review.35 
Table 2- Reason for exclusion from full text 
Figure 1. Flow diagram of the literature search and screening process 
Critical Appraisal  
Critical appraisal with appropriate CASP tools led to exclusion of three studies due poor 
methodology or not enough information. 22, 29, 35 See Table 3 for summary of the critical appraisal. 
The three studies excluded at this stage had a large majority (>75%) of negative answers or “can’t 
tell” when the CASP tools were applied. A cohort study by Watanabe Nemoto appears to have 
recorded pain scores by sending a questionnaire to patients after the procedure had been 
completed, however sedation was given throughout the procedure.29 Therefore an overall pain score 
would be potentially unreliable and likely to indicate whether a woman can remember experiencing 
pain.29 Recruitment to this study is unclear as they report that 57 patients received 178 sessions of 
brachytherapy, however only 74 questionnaires were returned, and the number of women who 
responded is not reported. The two researchers were unable to understand the method or results of 
this study. A case control study by Rollison and Strang compared experiences of women undergoing 
cervical brachytherapy with women having palpation (examination) under anaesthesia for a 
gynaecological cancer.22 The LDR brachytherapy meant that women had to lie flat with applicators in 
place for 15 to 20 hours. The two researchers agreed that the control group was inappropriate and 
gave no information that would not have been obvious at the outset. For example 8/20 women lying 
flat for brachytherapy would have preferred an alternative menu compared to 18/20 women in the 
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control group who approved of the food. This study was considered by the two researchers to be 
unsuitable to include in data extraction and synthesis. A literature review by Barros and Labate only 
used 2 search terms and did not include any databases of nursing journals.35 There was no reported 
quality assessment of the included studies. The results and discussion are combined and both 
researchers found the findings were unclear and therefore deemed this study not appropriate for 
data extraction or synthesis for this SLR. 
Table 3 Summary of the critical appraisal. 
The nineteen remaining studies included twelve studies focusing on psychological and seven on 
pharmacological aspects of experiences of brachytherapy. Ten of the twelve psychological studies 
explored the lived experiences of women undergoing brachytherapy for gynaecological cancer. Two 
studies investigated interventions to improve the experiences of women during treatment. Themes 
of anxiety, distress, pain, informational needs and non-pharmacological interventions were found. 
Table 4 Characteristics of studies for data extraction and synthesis 
Data extraction and synthesis 
Anxiety and distress 
Of ten studies regarding psychological issues, nine reported that brachytherapy caused anxiety and 
distress for most women.12, 23, 26, 27, 30, 31, 32, 33, 34 However Nail found the procedure was well tolerated 
without high levels of distress, depression or anxiety in most women.28 Anderson et al described 
anxiety levels taking a long time to reduce, following completion of treatment.23 They found that 
patients’ reports of anxiety were higher than assessed by nurses and doctors, which suggests that 
staff underestimated anxiety and/or that patient’s disguised or under-reported anxiety .23 It was also 
found that anxiety levels were not reduced prior to the second treatment, concluding that women 
did not adapt.23 Kamer et al evaluated influencing factors and found anxiety significantly lower for 
married or widowed women and those with two or more children.26 Warnock found incidence and 
severity of anxiety and distress was variable, presenting a challenge for nurses to provide 
appropriate care.34 Kirchheiner et al found that brachytherapy was more stressful than other 
gynaecological cancer treatments with 30% having acute stress disorder one week after and 41% 
having post-traumatic stress disorder (PTSD) at three months. Predictive factors for PTSD were a 
history of sexual violence, poor performance status, higher anxiety levels and lower emotional 
functioning. Examples of direct quotes from women described the experience as “...like having no 
chance to defend myself against a rape” and “a debasing situation”.12 
Pain 
Experiences of women receiving up to five outpatient HDR procedures described pain as mild to 
moderate for most but severe for 9%.27 Significant recall of pain from previous brachytherapy was 
reported by 29-59% with the amnesic effect being less than anticipated. In contrast to this, distress 
decreased with each procedure.27 The duration of the procedure was 2-3 hours with a mean of 127 
minutes. A study from South Africa examined HDR brachytherapy with quick outpatient 
procedures.30 The women reported negative experiences causing fear, pain and humiliation. They 
compared brachytherapy to childbirth with high levels of complex pain and described brachytherapy 
as their “worst experience”. The authors recommended better pain management strategies and 
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non-drug options to complement pharmacological management. They advised minimising observers 
and staff changes and providing individualised patient information. 30 Another study reported that all 
participants had varying degrees of pain, but that it was not as bad as expected and that discomfort 
was experienced as a totality, not limited to pain. 33 Kirchheiner et al reported that pain was the 
most frequently reported stressful experience during brachytherapy. 12 
Informational needs 
Two studies reported women’s experiences of lack of information before the procedure. 31, 33 Long et 
al focussed entirely on informational needs and concluded that women needed more information 
about their disease, preparation for treatment, the treatment itself, side effects and sexual 
intercourse. 31 They concluded that information should be delivered verbally and written in the 
patient’s home language.31 
Pharmacological studies 
Seven studies reported investigations of pain medication during gynaecological brachytherapy and 
are summarised in Table 5. These were published from 1998 to 2017, but all reported on HDR 
techniques. All studies used a form of the 11 point Visual Analogue scale to record post-operative 
pain. There were five studies where patients received day case HDR brachytherapy with pain 
management only required for a few hours.16, 18, 20, 21, 25 Overall there are a number of different 
approaches to peri and post-operative pain management, and it is inconclusive which method is 
superior, but duration of analgesia is a key factor in determining which method is chosen. 
Table 5 Pharmacological studies data extraction summary and reviewer comments. 
Non-pharmacological interventions 
Two studies examined effects of non-pharmacological interventions. Leon-Pizzaro et al investigated 
the effect of relaxation and guided imagery during brachytherapy on anxiety and depression.19 This 
RCT included 66 women receiving LDR brachytherapy for either breast or gynaecological cancer, with 
two thirds having brachytherapy for gynaecological cancer. Duration of treatment was typically two 
days. They reported significant reductions in anxiety, depression and body discomfort in the 
relaxation and guided imagery group compared to the control arm.19 Chi et al explored the effects of 
a music relaxation video on pain and anxiety with a RCT of 60 women receiving PDR brachytherapy.17 
They delivered a music relaxation video four times during the first 44 hours of brachytherapy. 
Perceived pain and anxiety levels were significantly lower in the music relaxation group compared to 
the control group. They reported a significant reduction in pain after use of the music video 
indicating that relaxation can reduce pain. 17 Both studies showed significant benefits from their non-
pharmacological experimental interventions.  
Discussion 
Overall the nineteen studies included in this SLR show that brachytherapy causes pain, anxiety and 
distress and identified a need for better information provision. It was also found that different 
pharmacological and non-pharmacological approaches can improve women’s experiences of 
brachytherapy. Factors influencing decisions about how to implement dose escalation and reduce 
toxicity, by implementing new techniques and technological advances to improve local control, are 
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often based around availability of staff and facilities, such as access to imaging, planning, anaesthetic 
resources and extra time needed for clinical oncologists, physicists and radiographers. However, the 
psychological impact for women undergoing the treatment has not been reported as an influencing 
factor within any reports of implementation of developments or clinical guidelines. The 
development of HDR brachytherapy from LDR techniques was originally welcomed as an 
improvement which would allow short day case procedures that would be more tolerable for 
women. Longer duration for increasingly complex planning requirements, such as extra dose points 
and constraints for EMBRACE II study36 and longer treatments such as PDR or multiple HDR fractions 
per insertion over a number of days would seem likely to increase anxiety and distress. Some studies 
reported no decrease, or sometimes an increase in anxiety for subsequent insertions and concerns 
raised that women did not adapt and were not re-assured after their first treatment.24, 27, 30 
Therefore it is possible that multiple day case procedures may lead to a re-traumatisation for 
women if their first experience of brachytherapy caused distress. 
An international survey of practice reported that 97% of 72 respondents used some form of 
anaesthesia with insertion of brachytherapy applicators9 and the findings are referred to in the 
American Brachytherapy Society (ABS) Guidelines general principles.10 However, only two of the 
seven pharmacological studies describe analgesia and anaesthesia techniques which would be 
applicable to centres which deliver HDR brachytherapy with a longer time period with applicators in 
place.11, 23 Effective pain management for short procedures taking less than 2 hours in total is 
unlikely to be applicable for this longer duration technique, or when interstitial needles are added. 
Local anaesthetic spray onto the cervix or conscious sedation would not provide the required 
duration of analgesia, especially if interstitial needles are introduced. Wiebe et al suggested that this 
multi-fraction technique required greater vaginal packing to secure the applicators in place for the 
prolonged duration when compared with a single fraction technique, and may have contributed to 
higher levels of pain.11 Interestingly this centre used PCA opioid pump for post-operative pain 
control for interstitial techniques and oral/intravenous analgesia for intracavitary techniques, 
acknowledging that interstitial needles required different analgesia. The use of oral transmucosal 
fentanyl citrate for brachytherapy procedures has been previously reported.37 This may provide 
another option for procedure analgesia or for breakthrough pain at identified points in the 
procedure likely to cause higher pain, such as transfers for imaging or during applicator removal. 
Various techniques will be developed in centres with different resources or constraints, and 
following guidelines may be useful when new techniques are introduced. The Groupe Européen de 
Curiethérapie and European Society for Radiotherapy & Oncology (GEC-ESTRO), The Royal College of 
Radiologists (RCR) and ABS guidelines for treatment of locally advanced cervical cancer have been 
developed. 10, 38, 39, 40, 41, 42 However their main focus is to standardise planning and dose reporting. 
There is little or no mention of the delivery of clinical aspects relating to patient experience, 
psychological repercussions and any impact on quality of life after treatment. The use of a standard 
method of measuring and recording patient’s pain scores could assist in auditing and developing 
best practice for pain management. 
The use of non-pharmacological interventions could potentially be introduced to supplement the 
essential pharmacological approaches and provide women with some control over their own 
wellbeing during brachytherapy. Relaxation and guided imagery and a music relaxation video 
showed significant benefits for women undergoing long duration brachytherapy procedures.17, 19 
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They were found to be simple, effective, non-invasive and cheap. Overall it can be surmised that 
these supplementary interventions may be beneficial to some women during brachytherapy. 
Conclusion 
There are a multitude of studies reporting technical advances and clinical implications of 
implementing new developments, but a lack of studies examining patient experiences in this 
context. This SLR showed that brachytherapy for gynaecological cancer can cause varying levels of 
pain, anxiety and distress. There is a need for better pain management, patient information and 
support and the development of non-pharmacological interventions to improve experiences. 
Pharmacological approaches should be explored and developed to minimise pain and discomfort 
throughout the procedure, including applicator insertion, patient bed transfers for imaging, waiting 
between fractions of dose delivery (if multiple doses per insertion) and applicator removal. 
Alongside optimal management of pain, women’s anxiety and distress maybe reduced by non-
pharmacological interventions. The development of clinical support guidelines may provide 
standards to improve women’s experiences of the treatment or to facilitate audit to evaluate the 
quality of service provision, especially when new techniques such as interstitial brachytherapy is 
introduced. Acquiring patient satisfaction feedback about brachytherapy could also give valuable 
information about which areas are most distressing or satisfactory and which pharmacological or 
non-pharmacological support was helpful. This may lead to development of effective interventions 
(both pharmacological and non-pharmacological) to improve women’s experiences of brachytherapy 
for locally advanced cervical cancer. 
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N = 20 
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N=  
N= 727 
Figure 1
Figure 1. Flow diagram of the literature search and screening process 
 
Figure 1 caption
Table 1- Key search terms 
 
Key words and search extent Search terms 
Cancer, neoplasm or tumour in all text cancer*, neoplasm*, tumo* 
AND 
Cervix or gynaecological in all text 
AND 
 
cervi*, gyn* 
Brachytherapy or intracavitary in all text brachytherapy*, intracavit* 
AND 
Anaesthesia, sedation or analgesia in all text 
OR 
 
anaesthesi*, anesthesi*, sedat*, analgesi* 
Anxiety, stress, anxious, PTSD, psychology, 
coping, phenomenon, distress in all text 
Anxiet*, stress*, anxious*, ptsd*, psychology*, 
coping*, phenomen*, distress* 
 
Table 1
Table 2- Reason for exclusion from full text 
 
 
Reason for exclusion Number of articles 
No full text available- conference abstract/poster only 12 
Full text not in English 4 
Duplicate discovered (author name different spelling, same patient cohort)  2 
Feature article, letter (opinions-not research) 2 
Literature study to develop an intervention, no patient data 
No patient experience found 
1 
3 
 
Table 2
Table 3 Summary of the critical appraisal 
3a. CASP tool for randomised controlled trials  Chen et 
al, 1998 
Chi et al, 2015 Jain et al, 
2007 
Leon-Pizzarro 
et al, 2007 
Thanthong et 
al, 2017 
Clearly focussed issue addressed?                Yes Yes Yes Yes Yes 
Assignment of patients randomised? Yes Yes Can’t tell Yes Yes 
Blinded patients, health workers and study personnel? Can’t tell Not possible Not possible Not possible Yes 
Groups similar at start? Can’t tell Yes Can’t tell Yes Yes 
Aside from intervention, groups treated equally? Yes Yes Yes Yes Yes 
All patients accounted for at conclusion? Yes Yes Can’t tell Yes Yes 
How large was treatment effect?? Significant Significant Significant Significant No difference 
How precise was estimate of treatment effect? p < 0.001 Small p values p = 0.038 Small p values High p values 
Results can be applied to the local population? Partially Yes Partially Yes Partially 
Were all clinically important outcomes considered? No Yes Yes Yes Yes 
Are benefits worth harms and costs? Yes Yes Yes Yes N/A 
Suitable quality for data extraction/synthesis Yes Yes Yes Yes Yes 
 
3b. CASP tool for cohort studies  Amsbaugh et 
al, 2016 
Anderson et 
al, 1984 
Bhannabhai 
et al, 2013 
Kamer et al, 
2007 
Kirchheiner 
et al, 2014 
Kwekkeboom 
et al, 2009 
Nail, 
1994 
Watanabe Nemoto 
et al, 2015 
Wiebe et al, 
2011 
Clearly focussed issue?                Yes Yes Yes Yes Yes Yes Yes Yes Yes 
Cohort recruitment acceptable? Yes Yes Can’t tell Yes Yes Yes Yes No Yes 
Exposure accurately measured to minimise bias? Yes Yes No Yes Yes Yes Yes No Yes 
Outcome accurately measured to minimise bias? Can’t tell Yes No Yes Yes Yes Yes No Yes 
Important confounding factors identified? Mostly Mostly No Yes Yes N/A Yes No Yes 
Confounding factors in design/analysis? No No No Yes Yes N/A Yes No Yes 
Follow up complete enough? N/A Yes No Yes Yes Yes Yes Can’t tell Yes 
Follow up long enough N/A No No No No No Yes Yes Yes 
Clear results? Yes Yes Yes Yes Yes Yes Yes No  Yes 
Precise results? Yes Yes Can’t tell Can’t tell Yes Yes Yes No Yes 
Believable results? Yes Yes Can’t tell Yes Yes Yes Yes No  Can’t tell 
Results can be applied to the local population? Partially Partially Partially Can’t tell Partially Partially Yes No Yes  
Results fit with other evidence? Yes Yes Yes Yes Yes Yes Yes Can’t tell Yes 
Value to practice? Yes Yes Limited Yes Yes Yes Yes No Yes 
Suitable quality for data extraction/synthesis Yes Yes Yes Yes Yes Yes Yes No Yes 
 
3c. CASP tool for qualitative research Velji & Fitch, 
2001 
Warnock, 
2005 
So & Chui, 
2007 
Dzaka et al, 
2016 
Long et al, 
2016 
Clear statement of aims?                Yes Yes Yes Yes Yes 
Qualitative methodology appropriate? Yes Yes Yes Yes Yes 
Research design appropriate? Yes Yes Yes Yes Yes 
Table 3
Recruitment strategy appropriate? Unknown Unknown Yes Unknown Yes 
Data collection clear/justified? Yes Yes  No Yes Yes 
Relationship between researcher & participants considered? Yes No Yes Partial Yes 
Ethical issues considered? Yes Unknown Yes Yes Yes 
Data analysis sufficiently rigorous? Yes No detail Yes Yes Yes 
Clear statement of findings? Yes Yes Yes Yes Yes 
Research valuable to current practice/policy/literature? Yes Yes Yes Yes Yes 
Suitable quality for data extraction/synthesis Yes Yes Yes Yes Yes 
 
3d. CASP tool for case control studies  Isoyama-Shirakawa 
et al, 2015 
Rollison & 
Strang, 1995 
Clearly focussed issue?                Yes Yes 
Appropriate method? Yes No 
Recruitment strategy appropriate? No No 
Acceptable selection of controls? Yes No 
Exposure accurately measured to minimise bias? Yes No 
Important confounding factors identified? Yes No 
Confounding factors in design/analysis? Yes No 
Clear results? Yes Yes 
Precise results? Yes Yes 
Believable results? Limited Yes 
Results can be applied to the local population? Partially No 
Results fit with other evidence? Yes Can’t tell 
Suitable quality for data extraction/synthesis Yes No 
 
3e. CASP tool for systematic review studies   Barros & Labate,  
2008 
Clearly focussed question?                Yes 
Appropriate papers searched? No 
Were all relevant studies included? No 
Sufficient quality assessment? No 
Combined results appropriate? N/A 
Clear results? No 
Precise results? No 
Results can be applied to the local population? Can’t tell 
Were all important outcomes considered? No 
Are benefits worth harms and costs? Can’t tell 
Suitable quality for data extraction/synthesis No 
 
 
Table 4 Characteristics of 19 studies for data extraction and synthesis in date order 
 
AUTHOR PUBL 
DATE 
COUNTRY STUDY DESIGN LDR/HDR/ 
PDR 
Anderson et al
24
 1984 USA Cohort study, prospective LDR 
Nail et al
28
 1993 USA Cohort study, prospective LDR 
Chen et al
16
 1998 China Randomised controlled trial HDR 
Velji and Fitch
33
 2001 Canada Qualitative, phenomenology LDR/PDR 
Warnock, C
34
 2005 UK Qualitative study, prospective HDR 
Jain et al
18
 2007 India Randomised controlled trial HDR 
Kamer et al
26
 2007 Turkey Cohort study, prospective HDR 
Leon-Pizzarro et al
19
 2007 Spain Randomised controlled study LDR 
So and Chui
32
 2007 Hong Kong Qualitative study LDR 
Kwekkeboom et al
27
 2009 USA Cohort study, longitudinal descriptive HDR 
Wiebe et al
11
 2011 Canada Cohort study, prospective HDR 
Bhanabhai et al
25
 2013 Canada Cohort study, retrospective observational  HDR 
Kirchheiner et al
12
 2014 Austria Cohort study, prospective observational pilot HDR 
Chi et al
17
 2015 USA Randomised controlled trial PDR 
Isoyama-Shirakawa et al
21
 2015 Japan Case control study- retrospective HDR 
Amsbaugh et al
23
 2016 USA Cohort study, retrospective HDR 
Dzaka and Maree
30
 2016 South Africa Qualitative study, descriptive HDR 
Long et al
31
 2016 South Africa Qualitative, prospective, phenomenology HDR 
Thanthong et al
20
 2017 Thailand Randomised controlled trial HDR 
 
Table 4
Table 5 Pharmacological studies data extraction summary 
Author   Study Aim Study design Population/context Intervention Results Authors 
Recommendations 
Reviewers comment 
Chen et al, 
1998 
To investigate the 
effect of local 
vaginal anaesthesia 
on pain relief and 
safety by 
monitoring serum 
levels 
RCT 40 patients with 
cervical cancer, 5 
treatments each. 
Short duration- 
outpatient 
procedure 
GA for 1st trt. Then 
randomised to trt-
control-trt or control-trt-
control-trt. Trt: lidocaine 
10% sprayed onto cervix 
for 5 mins. Control- 
Placebo spray. 
Meperidine injection for 
all. No GA 
10% lidocaine solution 
significantly decreased degree 
of painful sensation. Mean 
pain score 49.9 ± 24.1 SD; 
control mean 60.1 ± 24.8 SD. 
Sig difference P<0.001. No diff 
in physiological response or 
adverse effects. Serum levels 
didn't rise to unsafe levels. 
Safe and effective 
method for 
analgesia.  
Still had mean moderate 
pain scores compared 
with GA or 
spinal/epidural. 
Only suitable for short 
duration procedures. 
Jain et al, 
2007 
To compare 3 
different 
anaesthetic 
techniques, quality 
of analgesia and 
side effects. 
RCT 35 women with 
cervical cancer, 
divided into 3 arms, 
Typically 1½ - 2 
hours overall time, 
3 treatments each, 
1 per week. 
Group A- subarachnoid 
block, Group B- GA with 
laryngeal mask airway, 
Group C - GA with face 
mask. Measured pain, 
motor block, sedation 
level, nausea and 
vomiting and post-
operative analgesia 
requirements. 
Significantly less analgesia 
required by group A.  P = 
0.038. No sig difference in 
post op nausea and vomiting. 
No sig diff in sedation level. 
Overall 24.7% had mild pain, 
18.1% moderate pain and 
5.7% severe pain. Higher 
complication rates with GA. 
Regional 
anaesthesia 
provides better 
post op analgesia 
than GA. 
Difficult to know if this 
could be applicable to 
longer duration schedules, 
PDR and multiple HDR trts 
per insertion. 
Wiebe et 
al, 2011 
To assess adequacy 
of analgesia and 
symptom control 
with multiple 
fractions of HDR 
brachy during a 
single applicator 
insertion 
Prospective 
cohort  
18 patients with 
gynaecological 
cancers recruited. 
Data from 17. 
14 intracavitary and 
3 interstitial. 
Typical duration 25-
36 hrs. 
GA for insertion. 
Transferred to oral or 
subcut anaesthesia after 
GA. Interstitial had PCA 
pump after GA. 
Tolerability assessed by 
pain scores, anxiety and 
nausea, 5 time points: 
baseline, transfer to CT 
couch, after 1st trt, 
immediately after 
applicator removal, 
follow up (time point not 
specified). 
Mean pain scores highest 
after CT transfer 3.3 ± 2.6 SD. 
Was 0.9 ± 1.7 SD at baseline. 
5 pts reported no pain. Not sig 
higher pain with interstitial, 
3.3 vs 2.3, P=0.42. Anxiety 
score highest before brachy 
4.3 ± 3.4. During procedure 
resolved to 1.3 ± 1.6 SD. 
Slightly higher at FU appt 1.6 
± 1.5 SD. Nausea mode score 
= 0. Severe pain (7-10) in 4/17 
pts, all at CT transfer + 1 after 
trt delivery, 1 at FU appt. Also 
3 pts had severe anxiety, all at 
baseline. 
Overall only mild 
pain and anxiety. 
Discussed 
anticipatory 
anxiety. Pre-
emptive analgesia 
at specific points. 
Consider studies 
on management 
of emotional 
distress such as 
guided imagery or 
music relaxation. 
Underestimate/ignoring 
severe pain- reported in 
4/17 at specific time 
point.  
Small number of 
participants. 
Overall good pain 
management therefore 
applicable to longer 
duration procedures. 
Table 5
Bhanabhai 
et al, 2013 
To assess the 
effectiveness of 
conscious sedation 
Retrospective 
observational  
20 patients with 
cervical cancer, 57 
procedures. Weekly 
outpatient 
procedure. Median 
duration 1.4 hours. 
Pain scores recorded 
every 10 mins and at key 
points during HDR brachy 
procedure. Qualitative 
notes by nursing staff. 
Satisfaction with pain 
control recorded in 
recovery room. 
Midazolam and opioid 
used. 
Good pain control achieved 
with conscious sedation. Brief 
moments of moderate to 
severe pain mostly when ring 
and tandem applicator 
inserted. Maximal pain ranged 
from 0-10, mean 4.7. All pts 
satisfied with pain control.  
Effective regime. 
Fentanyl now 
opioid of choice as 
fast onset and 
rapid clearance. 
May only be suitable for 
short duration 
procedures. 
Patient satisfaction 
scoring not explained. 
Isoyama-
Shirakawa 
et al, 2015 
To investigate the 
effects of caudal 
epidural 
anaesthesia 
Retrospective 
case control  
34 women with 
cervical cancer. 
Control group, 
earlier time period, 
30 pts cervical 
cancer, same 
applicator. 4 trts in 
control group, 5 in 
anaesthesia group, 
no duration but 
likely to be short 
outpatient trt 
Experimental group had 
caudal epidural with 
mepivicaine + other 
analgesia or sedation. 
Control group had 
analgesia and sedation 
only- no anaesthesia. 
Caudal epidural success rate 
97%. Patient reported pain 
scores sig less for anaesthesia 
group (P=0.038 and P=0.037). 
Outcomes from 30 pts only. 
Mean score 5.17 ± 2.97 SD vs 
6.8 ± 2.59 SD (P=0.035). 
Lower use of sedation but 
higher use of opiates in 
anaesthesia group. No 
complications from caudal. 
Caudal is an 
option for safe 
and effective 
regional 
anaesthesia. 
High levels of pain in 
caudal epidural group 
compared to other 
studies. May not have 
blocked pain caused by 
applicators in uterus. May 
give better block for 
cervix, vagina and 
perineum, not uterus. 
Could be applicable to 
short brachy procedures, 
not PDR or HDR with 
multiple trts per insertion. 
Amsbaugh 
et al, 2016 
To determine 
optimal epidural 
anaesthesia for 
interstitial brachy 
for gynaecological 
cancers 
Retrospective 
cohort 
71 patients with 
gynae cancers (35 
cervix, 16 vagina, 13 
uterus, 7 vulva), 
Interstitial 
brachytherapy 
3 arms: 
12 ropivocaine only; 59 
opioid + ropivicaine. 
Subgroup: 14 fentanyl + 
ropivicaine; 45  
hydromorphone + 
ropivicaine  
More pain in ropivicaine only 
group, needed more 
additional opiates, suggests 
inadequate pain control.; no 
difference in nausea 
Combined 
modality epidural 
improves pain 
control, opioid 
with local 
anaesthetic, 
compared with 
local anaesthetic 
alone 
All Interstitial cases, but 
analgesic technique may 
still be applicable to 
Intracavitary or hybrid 
techniques. 
Thanthong 
et al, 2017 
To compare the 
effectiveness of 
two sedative 
regimens in 
relieving pain 
RCT, double 
blind 
crossover 
40 pts, 160 
treatments, all 
cervical cancer 
4 treatments each, 
typically 2-3 hours. 
Benzodiazepine to all, 
then 2 x fentanyl and 2 x 
meperidine. Researchers, 
HCPs and patients 
blinded. Pain score 
before intervention and 
every 15 minutes. If pain 
score >4 then an 
Treatment effect- no sig 
difference in effectiveness of 
sedation types. Pain peaked at 
45 minutes. Most experienced 
moderate pain during 
procedure, similar to other 
studies. 
No significant 
difference 
therefore 
cheapest sedation 
is appropriate. 
Applicable for day case 
HDR brachy, but not for 
multiple # as duration too 
long.  
additional opioid was 
given. QoL using EQ-5D. 
Abbreviations key: RCT Randomised controlled study; GA general anaesthetic; trt treatment; pts patients; gynae gynaecological; SD = Standard Deviation 
